Vivos Therapeutics enters $1.1M convertible note to fund pending SCN acquisition

Vivos Therapeutics, Inc.

$1.1M principal convertible note to V-Co Investors 2 LLC; net funding $1M after $100k fee.
Zero interest unless default; default rate 15% p.a.; secured by equipment only on default.
Converts automatically into equity of subsequent financing expected at SCN closing (target July 31, 2025).
Proceeds to fund previously announced acquisition of The Sleep Center of Nevada.
V-Co is affiliate of existing investor New Seneca Partners Inc.

item 1.01item 2.03item 3.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.